The altering cellular components and function in tumor microenvironment during remissive and relapsed stages of anti-CD19 CAR T-cell treated lymphoma mice
Anti-CD19 chimeric antigen receptor (CAR) T cells represent a highly promising strategy for B-cell malignancies. Despite the inspiring initial achievement, remission in a notable fraction of subjects is short-lived, and relapse remains a major challenge. Tumor microenvironment (TME) was proved to be...
Main Authors: | Kai Zhao, Chunxiao Ren, Donghai Tang, Li Zhao, Xianxian Chen, Ying Wang, Kailin Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1101769/full |
Similar Items
-
A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models
by: Wing Keung Chan, et al.
Published: (2023-09-01) -
Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
by: Hujun Li, et al.
Published: (2022-10-01) -
CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives
by: Semira Sheikh, et al.
Published: (2022-08-01) -
Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma
by: Yi Li Jiang, et al.
Published: (2024-02-01) -
Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma
by: Peiling Zhang, et al.
Published: (2022-10-01)